CoChat

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

Schmitt, Michael, Schmitt, Anita, Rojewski, Markus T., Chen, Jinfei, Giannopoulos, Krzysztof, Fei, Fei, Yu, Yingzhe, Götz, Marlies, Heyduk, Marta, Ritter, Gerd, Speiser, Daniel E., Gnjatic, Sacha, Guillaume, Philippe, Ringhoffer, Mark, Schlenk, Richard F., Liebisch, Peter, Bunjes, Donald, Shiku, Hiroshi, Dohner, Hartmut, Greiner, Jochen · 2008 · Blood
Cited by 212

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The receptor for hyaluronic acid–mediated motility (RHAMM) is an antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and multiple myeloma (MM). We initiated a phase 1 clinical trial vaccinating 10 patients with R3 (ILSLELMKL), a highly immunogenic CD8+ T-cell epitope peptide derived from RHAMM. In 7 of 10 patients, we detected an increase of CD8+/HLA-A2/RHAMM R3 tetramer+/CD45RA+/CCR7−/CD27−/CD28− effector T cells in accordance with an increase of R3-specific CD8+ T cells in enzyme linked immunospot (ELISpot) assays. In chromium release assays, a specific lysis of RHAMM-positive leukemic blasts was shown. Three of 6 patients with myeloid disorders (1/3 AML, 2/3 MDS) achieved clinical responses: one patient with AML and one with MDS showed a significant reduction of blasts in the bone marrow after the last vaccination. One patient with MDS no longer needed erythrocyte transfusions after 4 vaccinations. Two of 4 patients with MM showed a reduction of free light chain serum levels. Taken together, RHAMM-R3 peptide vaccination induced both immunologic and clinical responses, and therefore RHAMM constitutes a promising target for further immunotherapeutic approaches. This study is registered at http://ISRCTN.org as ISRCTN32763606 and is registered with EudraCT as 2005-001706-37.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-07-099366

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 212

Metadata

Authors
Schmitt, M., Schmitt, A., Rojewski, M. T., Chen, J., Giannopoulos, K., Fei, F., Yu, Y., Götz, M., Heyduk, M., Ritter, G., Speiser, D. E., Gnjatic, S., Guillaume, P., Ringhoffer, M., Schlenk, R. F., Liebisch, P., Bunjes, D., Shiku, H., Dohner, H., & Greiner, J.
Venue
Blood
Published
2008-02-01
Volume
111
Issue
3
Pages
1357-1365
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2069382319
Cited by
212
References
3
FWCI
4.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. https://app.cochat.ai/papers/10.1182/blood-2007-07-099366
The paper
Schmitt, M., Schmitt, A., Rojewski, M. T., Chen, J., Giannopoulos, K., Fei, F., Yu, Y., Götz, M., Heyduk, M., Ritter, G., Speiser, D. E., Gnjatic, S., Guillaume, P., Ringhoffer, M., Schlenk, R. F., Liebisch, P., Bunjes, D., Shiku, H., Dohner, H., & Greiner, J. (2008). RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. https://doi.org/10.1182/blood-2007-07-099366

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.